NLS Pharmaceutics (NLSP) and Kadimastem announced that Kadimastem has issued a notice to convene a special general meeting of Kadimastem’s shareholders to approve the merger transaction with NLS. The Central District Court in Israel has approved that this meeting may occur within a reduced time frame of only 14 days from the date of publication of the meeting notice. This meeting is needed to secure Kadimastem’s shareholder approval which are critical to completing the merger process.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NLSP:
- NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising
- NLS Pharmaceutics Shareholders Approve Meeting Agenda
- NLS Pharmaceutics and Kadimastem Move Forward with Merger Plans
- NLS Pharmaceutics, Kadimastem announce filing of F-4 Registration Statement
- NLS Pharmaceutics Calls Extraordinary Meeting for Major Capital Restructuring